Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

Regulatory T cells (Treg) are abundant in human and mouse pancreatic cancer. To
understand the contribution to the immunosuppressive microenvironment, we depleted …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated
fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of …

Pancreatic Adenocarcinoma | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

KRAS is the most frequently mutated oncogene in human cancer. In addition to holding this
distinction, unsuccessful attempts to target this protein have led to the characterization of …